Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
LFW Photonics Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Avalo Therapeutics, Inc. - Common Stock
(NQ:
AVTX
)
14.80
+1.02 (+7.40%)
Streaming Delayed Price
Updated: 11:10 AM EDT, May 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Avalo Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Avalo Therapeutics Purchases Optional Milestone Buyout
April 28, 2026
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
March 23, 2026
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics to Participate in Upcoming Investor Conferences
February 24, 2026
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
February 18, 2026
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics to Participate in Upcoming Investor Conferences
February 04, 2026
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
November 06, 2025
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics to Participate in Upcoming Investor Conferences
November 03, 2025
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
October 29, 2025
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
October 01, 2025
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors
September 22, 2025
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics to Participate in Upcoming Investor Conferences
August 27, 2025
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates
August 07, 2025
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics to Participate in Upcoming Investor Conferences
June 23, 2025
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
June 18, 2025
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics to Participate in Upcoming Investor Conferences
May 27, 2025
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates
May 12, 2025
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference
April 30, 2025
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
March 26, 2025
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Reports 2024 Financial Results and Recent Business Updates
March 20, 2025
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics to Participate in Upcoming Investor Conferences
February 24, 2025
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
February 04, 2025
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
January 02, 2025
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
November 12, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics to Present at Upcoming Investor Conferences
November 11, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
November 07, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
October 08, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Announces Participation in September Investor Conferences
September 04, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 12, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
July 16, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
July 09, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
